Sunitinib Nanoparticles and Nanogel for Sustained AMD Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for age-related macular degeneration (AMD) suffer from a narrow therapeutic index, rapid drug clearance, frequent dose instillation requirements, and adverse effects, necessitating a formulation for local delivery of sunitinib to minimize dose frequency and enhance therapeutic effectiveness.
Innovation Solution
Development of poly(lactic-co-glycolic acid) (PLGA)-based nanoparticles loaded with sunitinib, combined with a thermal reversible nanogel, for sustained drug release at the target site, reducing dosing frequency and improving anti-angiogenesis effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current anti-VEGF therapies are administered systemically or via frequent intravitreal instillation, then therapeutic coverage is achieved, but dosing frequency must be frequent due to rapid clearance and narrow therapeutic index
Solution Approach 1:
The patent embeds sunitinib-loaded PLGA nanoparticles within a thermo-reversible nanogel matrix, creating a nested structure where the inner nanoparticle delivery system is contained within the outer gel formulation. This nested architecture enables sustained drug release over extended periods, reducing dosing frequency while maintaining therapeutic effectiveness in AMD treatment
Solution Approach 2:
The patent utilizes thermo-reversible gelation properties to change the physical state of the nanogel formulation from liquid at room temperature to gel at body temperature. This parameter change enables the formulation to be easily administered via intravitreal injection and then remain localized at the injection site with sustained release kinetics, thereby reducing dosing frequency
2Reliability
If sunitinib is administered at higher doses to achieve therapeutic effect, then anti-angiogenesis efficacy is improved, but severe dose-dependent toxicity increases
Solution Approach 1:
The patent employs PLGA nanoparticles with controlled surface charge and size parameters to achieve localized accumulation of sunitinib at the retinal site. The nanoparticles exhibit enhanced uptake by retinal cells while minimizing systemic distribution, thereby achieving effective local concentrations for anti-angiogenesis without proportionally increasing systemic toxicity
Solution Approach 2:
The PLGA nanoparticle acts as an intermediary carrier that mediates the delivery of sunitinib to the retinal tissue. This intermediary system controls the release kinetics and cellular uptake of the drug, enabling effective therapeutic concentrations at the target site while reducing the peak plasma concentrations that cause severe dose-dependent toxicity
3Reliability
If frequent dose instillation is performed to maintain therapeutic levels, then therapeutic effectiveness is maintained, but patient compliance decreases due to invasive procedures
Solution Approach 1:
The patent creates a continuous drug release system using the nanogel formulation that maintains therapeutic levels of sunitinib at the injection site over extended periods. The sustained release from the nanogel matrix eliminates the need for frequent re-institution, thereby maintaining therapeutic effectiveness while significantly improving patient compliance by reducing the frequency of invasive procedures
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The PLGA-based nanoparticles with sunitinib provide sustained delivery, decreasing dosing frequency and enhancing therapeutic efficacy by minimizing adverse effects and improving visual acuity in AMD patients.
Implementation Method 1
Nanoparticles (NPs) (e.g., Poly(lactic-co-glycolic acid) (PLGA)-based NPs) are used in the formulations of drugs due to their biocompatibility, biodegradability, and tailoring release profiles that can have release rates that range from days until months.
Implementation Method 2
Development of poly(lactic-co-glycolic acid) (PLGA)-based nanoparticles loaded with sunitinib, combined with a thermal reversible nanogel, for sustained drug release at the target site
Data Source
AI summary
Disclosed are nanoparticles and nanogel drug compositions and the use thereof for treating age-related macular degeneration.